Back in 2010, I wrote about all the strange and bizzaro
combinations of psychiatric drugs some of my adult patients had been put on by
other psychiatrists who had seen them before me. These combinations, in addition to being excessive, often made no sense from the standpoint
of what these drugs did in the central nervous system.
Uppers and downers and bears, oh my.
Uppers and downers and bears, oh my.
In the biz, this is known by some as malignant polypharmacy.
Sometimes polypharmacy is medically necessary because of disorders which
co-occur in certain patients (comorbidity), like patients who have both real bipolar disorder and panic disorder. However, a lot of times new drugs from different classes are added merely because
the first class of drugs used just did not do the job. And IMO, the most common reason
the first class of drugs fails is that the drugs were never indicated for the
patient’s underlying condition in the first place.
By now this practice has unfortunately spread to the lucrative field of drugging
children, where the use of more than one class of psychiatric drugs is becoming
more and more common. I have written about
how the use of psych drugs in kids is, in general, often higher in children who
have been subjected to a lot of stress and trauma, such as children in foster care
(9/20/10, 12/2/11). To me, this fact strongly
implies that behavior problems and reactions to stress are being misdiagnosed as mental
illnesses.
Higher prescription drug usage also seems to be inflicted more often on poor children, who have much less
access to good and more comprehensive psychiatric treatment (read: family
therapy), and whose underpaid doctors may give them short shrift.
In the United States, poor children are insured under Medicaid,
the U.S. Government’s medical plan for the poor. Medicaid pays psychiatrists
quite poorly, so most of them do not accept it. It is especially crappy at
covering family therapy.
So, it is hardly a surprise that a recent study of children on
Medicaid showed the following results, as reported by the American Psychiatric
Association’s newspaper, Psychiatric
News, on 6/26/14:
Use of second-generation antipsychotics (SGAs) concurrently with
other psychotropic medications in children in the Medicaid program has
increased over the last few years, according to a report published online in the Journal of American Academy of Child and
Adolescent Psychiatry.
Researchers at Children’s Hospital of Philadelphia used data from the Medicaid program to estimate the probability and duration of concurrent SGA use with different psychotropic medication classes over time and to examine concurrent SGAs in relation to clinical and demographic characteristics. Their analysis showed that while SGA use overall increased by 22%, about 85% of such use occurred concurrently with use of other psychotropic medications. By 2008, the probability of concurrent SGA use ranged from 0.22 for stimulant users to 0.52 for mood stabilizer users. The concurrent SGA use occurred for long durations (69%-89% of annual medication days).
Researchers at Children’s Hospital of Philadelphia used data from the Medicaid program to estimate the probability and duration of concurrent SGA use with different psychotropic medication classes over time and to examine concurrent SGAs in relation to clinical and demographic characteristics. Their analysis showed that while SGA use overall increased by 22%, about 85% of such use occurred concurrently with use of other psychotropic medications. By 2008, the probability of concurrent SGA use ranged from 0.22 for stimulant users to 0.52 for mood stabilizer users. The concurrent SGA use occurred for long durations (69%-89% of annual medication days).
The explanations for this phenomenon advanced by the senior
author, as reported by the story, were very telling:
David
Rubin, M.D., co-director of the Policy Lab at Children's Hospital of
Philadelphia. “In all likelihood, the use of the antipsychotics illustrates the
great challenge clinicians are having when responding to disruptive and
challenging behaviors in youth that don't neatly fit common diagnostic
categories. In a society that often doesn't offer other services to respond to
these behaviors, we should not be surprised how quickly the use of antipsychotics
has grown.”
So, he is almost declaring outright that antipsychotic drugs are being given
to children not for mental illnesses, but for disruptive behavior! If stimulants are involved, most of these children are undoubtedly being diagnosed with
ADHD. So, if other drugs are being added, it looks as if stimulants may not be working all that well for this problem in a significant number of cases. And yet, doctors and drug
companies and even the National Institute on Drug Abuse go on and on waxing eloquently about how impressively effective they are!
And when they are not working, then doctors are apparently adding
a drug meant for the almost non-existent condition of pediatric bipolar disorder.
I guess these kids have two mental illnesses. Maybe three. Yeah, right.
There is no evidence from clinical trials that the combination of these two drugs
is efficacious for anything, nor is there a physiological rationale for combining
them. And SGA’s are potentially very toxic, especially in children. And they still do a terrible job of even sedating acting-out kids.